- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05761795
소아 근시에 대한 IVMED-85의 효능
A Randomized, Vehicle-Controlled, Double-Masked Study of the Efficacy and Safety of IVMED-85 Ophthalmic Solution for the Treatment of Pediatric Myopia
To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.
The main aims are:
- Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics
- Assess the safety of a 12-month treatment of IVMED-85
Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.
연구 개요
상태
정황
상세 설명
This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.
Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.
Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.
The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.
A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Sarah Molokhia, RPH, PhD
- 전화번호: 385-229-4491
- 이메일: smolokhia@iveenamed.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.
- Are 5 to 10 years of age
- Have a minimum body weight of 15.45 kg (34 lbs)
- Willing and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
- Willing and able to comply with clinic visits and study-related procedures
- Able to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
- Willing and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
- Have refractive error as determined by cycloplegic autorefraction: myopia -0.50 D to -7.0 D (spherical equivalent); astigmatism ≤3.00 D; anisometropia ≤2.00 D
- Have BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
- Have corneal thickness between 450 and 680 μm
- Have IOP ≤22 mmHg
- Have axial length ≥20 mm and ≤27 mm
- Willing to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
- Willing to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: IVMED-85 Low Dose
Total subjects n=48, IVMED-85 low dose BID for 12 months |
Eye drop |
|
실험적: IVMED-85 High Dose
Total subjects n=48, IVMED-85 high dose BID for 12 months |
Eye drop |
|
위약 비교기: Placebo
Total subjects n=48, placebo BID for 12 months |
Eye drop |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Refractive error change from baseline at Month 12
기간: Baseline compared to month 12
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12 |
Baseline compared to month 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
기간: From screening to the end of treatment at 12 months
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
|
Change in optical biometrics
기간: From screening to the end of treatment at 12 months
|
Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits |
From screening to the end of treatment at 12 months
|
|
Refractive error at non-final study visits
기간: From screening to the end of treatment at 12 months
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12 |
From screening to the end of treatment at 12 months
|
|
Sub foveal choroidal thickness
기간: From screening to the end of treatment at 12 months
|
Change from baseline in sub foveal choroidal thickness in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
|
Accommodative amplitude in the spherical equivalent
기간: From screening to the end of treatment at 12 months
|
Change from baseline in accommodative amplitude in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression of high myopia
기간: From screening to the end of treatment at 12 months
|
Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12 |
From screening to the end of treatment at 12 months
|
|
Progression of prospectively identified progressive myopia
기간: From screening to the end of treatment at 12 months
|
Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records |
From screening to the end of treatment at 12 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Bala Ambati, iVeena Delivery Systems, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .